10-QPeriod: Q1 FY2001

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2001

Filed May 15, 2001For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported flat revenue for the first quarter of 2001, with total revenue of $91.4 million, matching the prior year's first quarter. Net income saw a slight decrease to $7.6 million from $8.0 million in the first quarter of 2000. The Companion Animal Group (CAG) experienced a 1% revenue decline, primarily due to reduced sales of consumables and feline test kits, though this was partially offset by growth in laboratory services and pharmaceuticals. The Food and Environmental Division (FED) showed a modest 3% revenue increase, driven by water testing products and livestock tests, despite a decline in dairy testing products. Cash flow from operations was negative $6.9 million, a significant change from the prior year's near break-even. This was largely driven by an increase in inventory. The company continues to actively repurchase shares, spending $13.0 million on treasury stock during the quarter. Management believes current cash and cash equivalents, along with operational cash flow, will be sufficient for future operations, but acknowledges risks related to product development, competition, regulatory approvals, and potential patent litigation.

Key Highlights

  • 1Total revenue for Q1 2001 was $91.4 million, virtually unchanged from Q1 2000.
  • 2Net income decreased to $7.6 million ($0.22 diluted EPS) in Q1 2001 from $8.0 million ($0.22 diluted EPS) in Q1 2000.
  • 3Companion Animal Group (CAG) revenue declined 1% due to lower consumable and feline test kit sales, partially offset by services and new pharmaceutical introductions.
  • 4Food and Environmental Division (FED) revenue grew 3%, driven by water testing products and livestock tests.
  • 5Cash used in operating activities was $6.9 million, a significant increase compared to the prior year's $0.2 million.
  • 6The company repurchased $13.0 million of its common stock in Q1 2001, continuing its share buyback program.
  • 7Inventories increased by $11.5 million, impacting operating cash flow.

Frequently Asked Questions

The flat revenue was primarily due to a decline in the Companion Animal Group (CAG), which saw reduced sales of consumables and feline test kits, a result of distributor inventory adjustments and a prior sales program. This decline was nearly offset by modest growth in the Food and Environmental Division (FED), driven by water testing products, and an increase in CAG's reference laboratory services and a new pharmaceutical product.

Cash flow from operations was significantly impacted by an $11.5 million increase in inventories. This buildup was attributed to contractual supply agreements for instrument consumables and development of pharmaceutical products nearing FDA registration. Additionally, changes in accounts payable and accrued expenses also contributed to the negative operating cash flow.

IDEXX expects its future success to depend on developing new products, facing intense competition from larger companies, navigating complex regulatory environments (especially for pharmaceuticals), and managing potential patent litigation. Risks include product development challenges, market acceptance of new offerings, competitive pressures, regulatory approval delays, and potential adverse outcomes in patent infringement claims. Fluctuations in quarterly results due to product mix, international sales, and distributor inventory management are also noted.

Yes, IDEXX continues to actively repurchase its common stock. In the first quarter of 2001, the company repurchased approximately 0.6 million shares for $13.0 million, as part of a Board-approved program to repurchase up to 10 million shares.